GlobeImmune (OTCMKTS:GBIM – Get Rating) and Pfizer (NYSE:PFE – Get Rating) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations and valuation.
Valuation and Earnings
This table compares GlobeImmune and Pfizer’s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| GlobeImmune | N/A | N/A | N/A | N/A | N/A |
| Pfizer | $100.33 billion | 2.20 | $31.37 billion | $5.48 | 7.13 |
Pfizer has higher revenue and earnings than GlobeImmune.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GlobeImmune | 0 | 0 | 0 | 0 | N/A |
| Pfizer | 0 | 8 | 5 | 0 | 2.38 |
Pfizer has a consensus price target of $48.80, indicating a potential upside of 24.94%. Given Pfizer’s higher possible upside, analysts clearly believe Pfizer is more favorable than GlobeImmune.
Profitability
This table compares GlobeImmune and Pfizer’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| GlobeImmune | N/A | N/A | N/A |
| Pfizer | 31.27% | 42.03% | 19.55% |
Insider and Institutional Ownership
67.6% of Pfizer shares are owned by institutional investors. 23.5% of GlobeImmune shares are owned by insiders. Comparatively, 0.1% of Pfizer shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Volatility and Risk
GlobeImmune has a beta of -179.87, meaning that its stock price is 18,087% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500.
Summary
Pfizer beats GlobeImmune on 8 of the 9 factors compared between the two stocks.
About GlobeImmune
GlobeImmune, Inc. is a biopharmaceutical company. It engages in the development of therapeutic products for cancer and infectious diseases based on its proprietary Tarmogen platform. The company was founded by Donald Bellgrau, Richard C. Duke, and Alex Franzusoff on February 10, 1995 and is headquartered in Louisville, CO.
About Pfizer
Pfizer Inc. is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Receive News & Ratings for GlobeImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlobeImmune and related companies with MarketBeat.com's FREE daily email newsletter.
